Senores Pharmaceuticals Limited has informed the Exchange regarding Monitoring Agency Report for quarter ended June 30, 2026

Date: July 27, 2026 To, To, Sr. General Manager Sr. General Manager BSE Limited National Stock Exchange of India Limited Listing Department Listing Department Phiroze Jeejeebhoy Towers Exchange Plaza, C-1, Block G Dalal Street Bandra Kurla Complex Mumbai – 400 001 Bandra (E), Mumbai – 400 051 BSE Scrip Code: 544319 NSE Symbol: SENORES Sub.: Monitoring Agency Report for the quarter ended June 30, 2026 Dear Sir/Madam, Pursuant to Regulation 32 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with Regulation 41 of the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018 , please find enclosed herewith Monitoring Agency Report for the quarter ended June 30, 2026, issued by CARE Ratings Limited (the “Monitoring Agency”), in respect of utilization of proceeds of the Initial Public Offer of the Company. The said report for the quarter ended June 30, 2026, has been duly reviewed by the Audit Committee and taken on record by the Board of Directors at their respective meetings held on July 27, 2026. The Monitoring Agency Report is also available on website of the Company i.e. www.senorespharma.com. You are requested to take the same on record. TFohra nSkeinnogr yeosu P. harmaceuticals Limited Deval Rajnikant Shah Whole Time Director & CFO DIN: 00332722 Enclosure: As above Senores Pharmaceuticals Limited 1101 to 1103, 11th Floor, South Tower, One42, Opp. Jayantilal Park, Ambali Bopal Road, Ahmedabad-380054, Gujarat, India P: +91 79 2999 9857 | E: info@senorespharma.com W: www.senorespharma.com | CIN No.: L24290GJ2017PLC100263 No. CARE/ARO/GEN/2026-27/1103 The Board of Directors Senores Pharmaceuticals Limited 1101 to 1103, 11th Floor, South Tower, One42, Ambli Bopal Road, Ahmedabad, Gujarat - 380054 July 27, 2026 Dear Sir, Monitoring Agency Report for the quarter ended June 30, 2026 - in relation to the IPO of Senores Pharmaceuticals We write in our capacity of Monitoring Agency for the Initial Public Offering (IPO) for the amount aggregating to Rs.500.00 crore of the Company and refer to our duties cast under regulation 41 of the Securities & Exchange Board of India (Issue of Capital & Disclosure Requirements) Regulations, 2018. In this connection, we are enclosing the Monitoring Agency Report for the quarter ended June 30, 2026 as per aforesaid SEBI Regulations and Monitoring Agency Agreement dated December 14, 2024. Request you to kindly take the same on records. Thanking you, Yours faithfully, Anuja Parikh Associate Director anuja.parikh@careedge.in Report of the Monitoring Agency Name of the issuer: Senores Pharmaceuticals Limited For quarter ended: June 30, 2026 Name of the Monitoring Agency: CARE Ratings Limited (a) Deviation from the objects: Nil (b) Range of Deviation: Not applicable Declaration: We declare that this report provides an objective view of the utilization of the issue proceeds in relation to the objects of the issue based on the information provided by the Issuer and information obtained from sources believed by it to be accurate and reliable. The MA does not perform an audit and undertakes no independent verification of any information/ certifications/ statements it receives. This Report is not intended to create any legally binding obligations on the MA which accepts no responsibility, whatsoever, for loss or damage from the use of the said information. The views and opinions expressed herein do not constitute the opinion of MA to deal in any security of the Issuer in any manner whatsoever. Nothing mentioned in this report is intended to or should be construed as creating a fiduciary relationship between the MA and any issuer or between the agency and any user of this report. The MA and its affiliates also do not act as an expert as defined under Section 2(38) of the Companies Act, 2013. The MA or its affiliates may have credit rating or other commercial transactions with the entity to which the report pertains and may receive separate compensation for its ratings and certain credit related analyses. We confirm that there is no conflict of interest in such relationship/interest while monitoring and reporting the utilization of the issue proceeds by the issuer, or while undertaking credit rating or other commercial transactions with the entity. We have submitted the report herewith in line with the format prescribed by SEBI, capturing our comments, s Management / Audit Committee of the Board of Directors subsequent to the MA submitting their report to the issuer and before dissemination of the report through stock exchanges. These sections have not been reviewed by the MA, and the MA takes no responsibility for such comments of the Signature: Name and designation of the Authorized Signatory: Anuja Parikh Designation of Authorized person/Signing Authority: Associate Director 1) Issuer Details: Name of the issuer : Senores Pharmaceuticals Limited Name of the promoters : Mr. Swapnil Jatinbhai Shah and Mr. Ashokkumar Vijaysinh Barot Industry/sector to which it belongs : Pharmaceuticals 2) Issue Details Issue Period : December 20, 2024 to December 24, 2024 Type of issue : Initial Public Offering Type of specified securities : Equity shares IPO Grading, if any : Not applicable Issue size (in Rs. crore) : Rs.500.00 crore of fresh issue 3) Details of the arrangement made to ensure the monitoring of issue proceeds: Source of information / certifications Comments of the Comments of the Particulars Reply considered by Monitoring Agency for Monitoring Agency Board of Directors preparation of report The Company has Ongoing delay in sought shareholder implementation in one of the approval for objects which was scheduled to variation in the Chartered Accountant certificate*; Whether all utilization is as per the disclosures in the get completed by FY26. Also, objects / terms of No Bank statement, Company Declaration, Offer Document? prior to this, there were delays in utilisation of IPO Management committee approval two other objects which were proceeds and completed in Q1FY26 instead of extension of time March 2025. limit through postal ballot. Whether shareholder approval has been obtained in Chartered Accountant certificate*; case of material deviations# from expenditures Not Applicable No material deviation No comments Bank statement, Company Declaration disclosed in the Offer Document? Whether the means of finance for the disclosed objects No Company declaration No comments No comments of the issue have changed? Chartered Accountant certificate*; Is there any major deviation observed over the earlier No Bank statement, Company Declaration, No observations No comments monitoring agency reports? Last monitoring agency report Source of information / certifications Comments of the Comments of the Particulars Reply considered by Monitoring Agency for Monitoring Agency Board of Directors preparation of report Whether all Government/statutory approvals related to Yes, as applicable Company declaration No comments No comments the object(s) have been obtained? Whether all arrangements pertaining to technical Not Applicable Company declaration No comments No comments assistance/collaboration are in operation? There is delay in setting up manufacturing facility for production of sterile injections at Are there any favourable/unfavourable events affecting Company declaration, stock exchange Yes Atlanta. This may affect the cost No comments the viability of these object(s)? filings parameters associated with it and associated benefits to the company. The company has sought shareholder approval for variation in the objects / terms of utilisation of IPO proceeds and extension of time limit by curtailing the objective-1 (to make investment in one of the subsidiaries, Havix, to fund capital expenditure requirements for setting up a Is there any other relevant information that may Company declaration, stock exchange manufacturing facility [Showing first 8,000 characters — download PDF for full document]